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Summary: A library of substituted pyrimidines was synthesized and evaluated for free 
radical scavenging, and in vitro cytotoxic activity in 3T3 cells. All compounds showed 
good free radical scavenging activity with IC50 values in the range of 42.9 ± 0.31 to 438.3 
± 3.3 µM as compared to the standard butylated hydroxytoluene having IC50 value of 
128.83 ± 2. 1 µM. The structure activity-relationship was also established. Selected 
analogues 1, 2, 3, 5, 6, 7, 8, 9, 10, 12, 13, 15, 19, 20, 21, 24, 25, 26 and 28 were tested 
for cytotoxicity in mouse fibroblast 3T3 cell line using MTT assay, and most of the 
analogues showed cytotoxicity. This study has identified a number of cytotoxic novel 
substituted pyrimidines having free radical scavenging activities that can be used as 
inhibitory compounds for those cancer cells whose growth is mediated by reactive 
oxygen species. 
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Introduction: 
 
Scavenging of free radicals by antioxidant 
compounds is an important biological 
function that may maintain in the body a low 
oxidative damage.1 Antioxidant compounds 
of different synthetic, and natural sources can 
scavenge these free radicals with the 
formation of less reactive species, and thus 
diminish the radical induced oxidative 
damage that is possibly associated with many 
diseases, including cancers.2-5 Numerous 
classes of synthetic compounds have been 
screened to reveal their free radical 
scavenging ability, including synthetically 
obtained deoxyribonucleic acids (DNA) and 
nucleotide analogues like pyrimidine 
                                                             
 
derivatives.6,7 These pyrimidines, present in 
numerous pharmaceutically important 
compounds, have been known to prevent 
cancer cell proliferation. Substituted 
pyrimidine primarily display their anticancer 
activity through intercalating with DNA 
nucleotide bases. However, they may prevent 
ROS induced DNA mutations in a way 
similar to other anticancer and antiviral 
molecules.8-11 In recent years, anticancer 
drugs already being used in medical practice 
or being tested in clinical studies have been 
often based on pyrimidine skeleton, and new 
pyrimidine derivatives continue to show 
promising activities.12-13 However, synthesis 
of antioxidant molecules can be a new 
approach to prevent proliferation of tumors 
whose growth is mediated by oxygen 
species.14 Besides their anti- tumor action, 
pyrimidine derivatives have also been found 
to possess additional biological activities 
including antibacterial, anti-folate, antibiotic, 
anti-HIV, anti-fungal, anti-mycobacterial, 
anti-leismanial were also found to inhibit 
tumor necrotic factor alpha (TNF-α) 
production.15 Herein, we report the free 
radical scavenging activities of a new library 
of pyrimidine derivatives to evaluate their 
potential against free radical sustained cancer 
cell proliferation. In the past, a number of 
pyrimidines were also found to inhibit 
enzymes such as tyrosine kinases, urease, β-
glucuronidase, and cholinesterase.16-18 
Furthermore, many pyrimidine analogues 
were found to exhibit inhibitory or 
modulatory activities in a number of 
biological situations.19, 20 Therefore, we 
screen these synthetic pyrimidine derivatives 
for their in vitro free radical scavenging 
activity as well as to establish their 
cytotoxicity in a 3T3 mouse fibroblast cell 
line. 
 
Scheme 1. Basic Skeleton of Pyrimidines. 
 
Experimental  
Material and Methods 
 
All substituted pyrimidines were obtained 
from the in-house Molecular Bank facility of 
the Dr. Panjwani Center for Molecular 
Medicine and Drug Research, International 
Center for Chemical and Biological Sciences, 
University of Karachi, Pakistan. DPPH was 
purchased from Sigma Aldrich (Germany). 
Ethanol and dimethyl sulfoxide (DMSO) 
(reagent grade) were purchased from Sigma 
Aldrich (USA). Standard compounds, i.e., 
butylated hydroxytoluene was purchased 
from Sigma Aldrich (Germany). 
 
DPPH Radical Scavenging Assay 
The Kumari Madhu method of DPPH (2,2-
diphenyl-1-picryl-hydrazyl) assay25 was used 
to measure the free radical scavenging 
activity with small variations. This assay is 
based on the reduction of DPPH radical 
(violet colour) by free radical scavenger with 
a change of colour to pale yellow. The 
intensity of colour conversion is directly 
related to the potency of free radical 
scavenging compounds, and to the extent of 
reduction in absorbance. In the visible region, 
absorbance reduction can be measure at 517 
nm. Compounds solutions of (0.5 mM) in 
DMSO were prepared. Two-fold dilution 
method was used to dilute compounds 
solutions to different concentrations. 5 µl 
sample of each concentration was transferred 
to 96 wells plate in triplet, at 517 nm pre read 
was recorded. 95 µl of 0.3 mM freshly 
prepared ethanolic solution of DPPH was 
added in each of the 96 wells. A final 
absorbance reading was taken at 517 nm. 
DMSO was used as negative control and 
butylated hydroxytoluene was used as the 
positive control. The radical scavenging 
activities were calculated by the following 
equation: 
% Radical scavenging activity of DPPH  
= [A0-A1/A0] ×100 
Where: 
A0: The absorbance of all reagents without 
the tested compounds. 
A1: The absorbance in the presence of test 
compounds. 
 
 
 
MTT Assay 
 
The pyrimidine derivatives were tested by the 
method previously described by Dimas et al. 
to establish their cytotoxicities in a normal 
cell line.26 In 96-well plate, mouse fibroblast 
3T3- cells (2 ×105 cells/ mL) were grown 
over night in DMEM medium along with 
10% FBS, pen/ strep (100 units/ mL), 
supplemented with 5% CO2 at 37 
ºC. After 24 
h, the old media was discarded, cells were 
treated with different concentrations of the 
tested compound, and further incubated for 
24 h. After 24 h, cells were washed, and the 
plate was again incubated with MTT solution 
for 4 h after which dimethyl sulfoxide 100uL 
added for 15 min to dissolved formazan 
crystals at room temperature. Finally, a micro 
plate reader (SpectraMax Plus-384) was used 
to record the absorbance at 540 nm. The IC50 
was calculated and defined as the drug 
concentration (µM) causing cytotoxicity in 
50%. cells.  
 
Results and Discussion 
Free Radical Scavenging Activity 
 
The synthetic pyrimidine derivatives 1-28 
were tested for their free radical scavenging, 
and cell cytotoxic potential. All compounds 
showed various degrees of radical 
scavenging activity inDPPH radical 
scavenging assay, and their IC50 values 
ranged between 42.9 ± 0.31 to 438.3 ± 3.3 
μM. Derivatives 1, 3, 11, 13, 18, 26, and 28 
with IC50 values of 55.6 ± 2.1, 122.4 ± 1. 9, 
107.65 ± 1.3, 108.4 ± 2.8, 113.4 ± 1.3, 42.9 ± 
0.31, and 65.7± 1.80 µM, respectively, 
showed free radical inhibitory activity that is 
many folds better than the standard butylated 
hydroxytoluene with IC50 value of 128.83 ± 
2.1 µM, as depicted in Figs. A-D, and Table-
1. Compounds 2, 5, 8, 12, 19, and 27 showed 
good to moderate activities (Fig. A-C and 
Table-1). The remaining derivatives, 
including 6, 7, 9,10, 15, 21, 22, 23, and 24 
showed weak inhibitory activities (Fig. A-D 
and Table-1). Derivatives 4, 14, 16, 17, 20, 
25 were decleared as inactive derivatives of 
this series. 
 
Table-1: Free radical scavenging activity of 
compounds (1–28). 
 
Cpds IUPC Names R IC50 ± SEMa 
(μM) 
1 5-(4-Hydroxy-
3,5-
dimethoxybenz
ylidene)-2-
thioxodihydrop
yrimidine-
4,6(1H,5H)-
dione 
 
55.6 ± 2.1 
2 5-(2-Bromo-
4,5-
dimethoxybenz
ylidene)-2-
thioxodihydrop
yrimidine-
4,6(1H,5H)-
dione 
 
198.2 ± 4.5 
3 5-((2-
Hydroxynaphth
alen-1-
yl)methylene)-
2-
thioxodihydrop
yrimidine-
4,6(1H,5H)-
dione 
 
122.4 ± 1.9 
4 5-(Thiophen-2-
ylmethylene)-2-
thioxodihydrop
yrimidine-
4,6(1H,5H)-
dione 
 
NA 
5 2-Thioxo-5-
(3,4,5-
trimethoxybenz
ylidene)dihydro
pyrimidine-
4,6(1H,5H)-
dione 
 
132.6 ± 1.2 
6 5-(4-
(Methylthio)ben
zylidene)-2-
thioxodihydrop
yrimidine-
4,6(1H,5H)-
dione 
 
209 ± 4.4 
7 5-((6-Bromo-4-
chloro-2-oxo-
2H-chromen-3-
yl)methylene)-
2-
thioxodihydrop
yrimidine-
4,6(1H,5H)-
dione 
 
322.4 ± 1.9 
8 5-(Pyridin-4-
ylmethylene)-2-
thioxodihydrop
yrimidine-4,6 
(1H,5H)-dione 
 
179.7 ± 6.2 
9 5-((6-
Methylpyridin-
2-
yl)methylene)-
2-
thioxodihydrop
yrimidine-4,6 
(1H,5H)-dione 
 
211.2 ± 4.6 
10 5-(4-Bromo-
2,5-
dimethoxybenz
ylidene)-2-
thioxodihydrop
yrimidine-4,6 
(1H,5H)-dione 
 
204.5 ± 3.5 
11 5-(3-Hydroxy-
4-
methoxybenzyli
dene)-2-
thioxodihydrop
yrimidine-4,6 
(1H,5H)-dione 
 
107.65 ± 1.3 
12 5-(3,4-
Dimethoxybenz
ylidene)-2-
thioxodihydrop
 
170.4 ± 2.5 
yrimidine-4,6 
(1H,5H)-dione 
13 5-(4-Hydroxy-
3-iodo-5-
methoxybenzyli
dene)-2-
thioxodihydrop
yrimidine-4,6 
(1H,5H)-dione 
 
108.4 ± 2.8 
14 5-(Anthracen-9-
ylmethylene)-2-
thioxodihydrop
yrimidine-4,6 
(1H,5H)-dione 
 
NA 
15 5-(2-Hydroxy-
4-
methoxybenzyli
dene)-2-
thioxodihydrop
yrimidine-4,6 
(1H,5H)-dione 
 
284.2 ± 5.9 
16 5-(2,4-Di-tert-
butyl-3-
chlorobenzylide
ne)-2-
thioxodihydrop
yrimidine-4,6 
(1H,5H)-dione 
 
NA 
17 5-(2-
Aminobenzylid
ene)-2-
thioxodihydrop
yrimidine-4,6 
(1H,5H)-dione 
 
NA 
18 5,5'-(1,4-
Phenylenebis(m
ethanylylidene))
bis(2-
thioxodihydrop
yrimidine-4,6 
(1H,5H)-dione) 
 
113.4 ± 1.1 
19 5-(3,5-
Dibromo-4-
hydroxybenzyli
dene)-2-
thioxodihydrop
 
170.8 ± 1.4 
yrimidine-4,6 
(1H,5H)-dione 
20 5-(4-
(Dimethylamin
o)benzylidene)-
2-
thioxodihydrop
yrimidine-4,6 
(1H,5H)-dione 
 
NA 
 
21 5-(2-
Methylbenzylid
ene)-2-
thioxodihydrop
yrimidine-4,6 
(1H,5H)-dione 
 
438.3 ± 3.3 
 
22 5-(4-
Ethoxybenzylid
ene)-2-
thioxodihydrop
yrimidine-4,6 
(1H,5H)-dione 
 
230.7 ± 2.6 
23 5-(2,4-
Dihydroxybenz
ylidene)-2-
thioxodihydrop
yrimidine-4,6 
(1H,5H)-dione 
 
231.9 ± 6.9 
24 5-(2-Hydroxy-
3-
methoxybenzyli
dene)-2-
thioxodihydrop
yrimidine-4,6 
(1H,5H)-dione 
 
200.6 ± 1.8 
 
25 5-((5-
Methylfuran-2-
yl)methylene)-
2-
thioxodihydrop
yrimidine-4,6 
(1H,5H)-dione 
 
NA 
26 5-(3,4-
Dihydroxybenz
ylidene)-2-
thioxodihydrop
yrimidine-4,6 
(1H,5H)-dione 
 
42.9 ± 3.6 
27 5-(2-Hydroxy-
5-
methoxybenzyli
dene)-2-
thioxodihydrop
yrimidine-4,6 
(1H,5H)-dione 
 
177.1 ± 3.6 
28 2-Thioxo-5-
(2,3,4-
trihydroxybenz
ylidene)dihydro
pyrimidine-
4,6(1H,5H)-
dione 
 
65.7 ± 1.8 
BHT
b 
2,6-Di-tert-
butyl-4-
methylphenol 
 
128.8 ± 2.1 
aSEM is the standard error of the mean, BHTb: Butylated 
hydroxytoulene  
 
Structure- Activity Relationship 
 
A structure-activity relationship established 
for all compounds that confirmed substitution 
of various functionalities at the aromatic ring 
confers free radical scavenging activity to 
each particular pyrimidine analogue. 
Analogue 26, a 3,4-dihydroxybenzylidene 
was found to be the most active pyrimidine 
among the series, with an IC50 value of 42.9 
± 0.31 μM, corresponding to 84.07% radical 
scavenging activity that is as good as 85.87% 
radical scavenging activity of the standard 
drug (Tables-1, and 3). The high activity 
shown by analogue 26 is due to the positional 
change of dihydroxyl groups present an 
aromatic moiety (Table-1). Literature reports 
have also shown that the phenolic hydroxyl 
group is responsible for the antioxidant 
function.21,24 Compound 1 is the second most 
potent derivative among the series, 
containing 4-hydroxy-3,5-dimethoxy groups 
with IC50 of value 55.6 ± 2.1 µM, with 
corresponding 91.58% radical scavenging 
activity (Tables-1, and 3). With 74.69% 
radical scavenging activity derivative 28, 
with three hydroxyl groups at 2,3, and 4-
positions, was found to be the third most 
effective derivative of the series (Tables-1, 
and 3). The lesser activity shown by analogue 
28 as compared to compound 26 might be due 
to the extra hydroxyl group which creates 
some steric hindrance (Table-1 and 3). In this 
study, we observed that all other hydroxyl 
group containing derivatives, such as 3, 11, 
13, 15, 19, 23 and 27, also showed 
antioxidant activity. The lesser activity 
shown by analogue 28 as compared to 
compound 26 might be due to the extra 
hydroxyl group which creates some steric 
hindrance (Table-1 and 3). In this study, we 
observed that all other hydroxyl group 
containing derivatives, such as 3, 11, 13, 15, 
19, 23 and 27, also showed antioxidant 
activity. The difference in their activity 
seems to be either due to the number, 
position, and presence of other substituents 
along with the hydroxyl group (Table-1). 
Compound 8, and 12 have almost identical 
free radical scavenging activity with 74.3%, 
and 90.76 % (Table-3). The moderate activity 
of compound 8 may be due to the lone pair of 
electrons on the pyridine nitrogen while in 
derivative 12, due to the presence of two 
methoxy groups (Table-1). Compound 7, and 
20 with (6-bromo-4-chloro-2-oxo-2H-
chromen-3-yl) and (6-bromo-4-chloro-2-
oxo-2H-chromen-3-yl) substitutions were 
found to be the least active of the series 
(Tables-1, and 3). The anthranyl analogue 14, 
di tert-butyl compound 16, derivative 17 
having aminobenzylidene, derivative 20 with 
dimethylamino group, methylfuryl molecule 
25, and thiophenyl derivative 4 did not show 
any antioxidant activity. 4-Bromo-2,5-
dimethoxy compound 10 and 2-bromo-4,5-
dimethoxy analogue 2 have the same 
substituents but their positions are different, 
providing little difference in their activities 
(Table-1). By changing the substituent from 
p-thiomethyl, as in analogue 6, to an amino 
groups such as N, N-dimethyl amino 
derivative 19 and methyl-2-pyridinyl 
molecule 9, it was observed the amino 
analogues showed greater radical scavenging 
activity than the one with p-thiomethyl and 
N, N-dimethyl amino functionalities. This 
might be due to the better ability of the 
former to provide free electrons (Tables-1, 
and 3). 
 
Cell Cytotoxic Activity 
 
Cytotoxicity of compounds 1, 2, 3, 5, 6, 7, 8, 
9, 10, 12, 13, 15, 19, 20, 21, 24, 25, 26 and 
28 was carried out by using mouse fibroblast 
3T3 cell line. Derivatives 1, 3, 5, 6, 8, 9, 12, 
13, 15, 19, 21, 24, 25, 26 and 28 exhibited 
non-cytotoxicity in mouse fibroblast 3T3 cell 
line (Table-3). Derivatives 7 and 20 were 
found to have weak cytotoxic effect with IC50 
values of 27.038 ± 0.26, and 22.4 ± 0.76, µM, 
respectively. However, compound 2 was 
found to be moderately cytotoxic with IC50 
value of 19.482 ± 0.406 µM, and only 
compound 10 was found to be cytotoxic with 
IC50 value of 7.038 ± 0.26 µM. 
 
Table-2: Cytotoxicity studies of selected 
pyrimidine derivatives. 
 
Compounds Cell 
Cytotoxicity 
IC50 (µM)± 
SEM 
Compounds Cell 
Cytotoxicity 
IC50 (µM) ± 
SEM 
1 >30 12 >30 
2 19.4 ± 0.4 13 >30 
3 >30 15 >30 
5 >30 19 >30 
6 >30 20 22.4 ± 0.7 
7 27.0 ± 0.2 21 >30 
8 >30 24 >30 
9 >30 25 >30 
10 7.0 ± 0.2 26 >30 
Cycloheximide 0.2± 0.1 28 >30 
 
SEM: standard error mean, cycloheximide standard drug 
 
 
 
 
 
 
Table-3: % RSA of selected derivative. 
 
% RSA: % Radical Scavenging Activity, Butylated 
hydroxytoulene (BHT) % RSA: 85.87 
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Cpds % Radical 
Scavenging 
Activity 
Cpds % Radical 
Scavenging 
Activity 
1 91.58 15 70.64 
2 89.25 16 2.61 
3 89.85 17 1.52 
4 13.45 18 75.84 
5 90.43 19 81.95 
6 78.00 20 19.29 
7 62.01 21 53.44 
8 74.35 22 70.78 
9 73.81 23 81.96 
10 75.00 24 81.72 
11 79.85 25 15.54 
12 90.76 26 84.07 
13 89.95 27 81.36 
14 34.92 28 74.69 
Figs. A-D: Free radical scavenging activities of pyrimidine derivatives (1–28) on deferent concentrations.  
Conclusion 
 
The present study identifies new series of 
pyrimidines as potential radical scavengers. 
All analogues were found to display diverse 
free radical scavenging potential when 
compared with the standard butylated 
hydroxytoluene. Compounds 1, 3, 11, 13, 17, 
25, and 27, with IC50 values of 55.6 ± 2.1, 
122.4 ± 1.9, 107.65 ±1.3, 108.4 ± 2.8, 113.4 
±1.3, 42. 9± 0.31, and 65.7 ± 1.80 µM, 
respectively, showed good free radical 
scavenging potential better than the standard 
butylated hydroxytoluene having IC50 value 
of 128.83 ± 2.1µM. Cytotoxic evaluation of 
selected derivatives further support our 
study. Compound 1, 13, and 25 were 
identified as non-cytotoxic against 3T3 cells; 
therefore, these can serve as lead compounds 
for further development as potential drug 
candidates to scavenge reactive oxygen 
species. 
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